BioCentury
ARTICLE | Clinical News

Bestatin: LIBERTY2 extension study started

February 1, 2017 9:44 PM UTC

Eiger began the open-label LIBERTY2 extension study of oral Bestatin for ≥24 weeks in about 45 patients who completed the double-blind, placebo-controlled, North American Phase II LIBERTY trial, which...